ENZYME REPLACEMENT THERAPY IN LYSOSOMAL STORAGE DISORDERS

被引:0
|
作者
BECK, M
机构
关键词
LYSOSOMAL STORAGE DISORDER; INBORN ERROR OF METABOLISM; ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; GM(2); GANGLIOSIDOSIS;
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
There are several strategies for the treatment of inborn errors of metabolism: Removal of toxic substrates is effective in disturbances of amino acid metabolism (e.g. phenylketonuria). Effective replacement of genetically deficient enzymes in metabolic disorders (particularly in lysosomal storage disorders) requires targeting of the enzyme to specific cells. Targeting can be achieved by entrapment of the enzyme into liposomes or by incorporation into red cell ghosts. While these efforts have not been rewarding, great success has been achieved in Gaucher disease by using modified beta-glucocerebrosidase: Careful removal of glycosidic side chains facilitates uptake of the enzyme by the storage cells (macrophages). Effective treatment of neurodegenerative lysosomal storage disorders by exogenous enzyme supply is hindered by the blood-brain barrier. In an animal model it has been demonstrated that effective lysosomal targeting of the enzyme Hexosaminidase A could be obtained by coupling it to an atoxic fragment of tetanus toxin.
引用
收藏
页码:240 / 244
页数:5
相关论文
共 50 条
  • [31] Enzyme replacement therapy versus substrate deprivation in the treatment of lysosomal disorders
    Aerts, J. M.
    CHEMISTRY AND PHYSICS OF LIPIDS, 2008, 154 : S19 - S19
  • [32] Delayed infusion reactions associated with enzyme replacement therapies for lysosomal storage disorders
    Utz, Jeanine
    Doyen, Colleen
    Whitley, Chester B.
    MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) : S40 - S40
  • [33] Non-inhibitory antibodies impede lysosomal storage reduction in enzyme replacement therapy of a lysosomal storage disease
    Matzner, U.
    Matthes, F.
    Herbst, E.
    Luellmann-Rauch, R.
    Weigelt, C.
    Andersson, C.
    Eistrup, C.
    Fogh, J.
    Gieselmann, V
    JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 : 124 - 124
  • [34] Role of the Lactide:Glycolide Ratio in PLGA Nanoparticle Stability and Release under Lysosomal Conditions for Enzyme Replacement Therapy of Lysosomal Storage Disorders
    del Moral, Maria
    Loeck, Maximilian
    Muntimadugu, Eameema
    Vives, Guillem
    Pham, Vy
    Pfeifer, Peter
    Battaglia, Giuseppe
    Muro, Silvia
    Andrianov, Alexander K.
    JOURNAL OF FUNCTIONAL BIOMATERIALS, 2023, 14 (09)
  • [35] Hypersensitivity reaction during enzyme replacement therapy in lysosomal storage disorders. A systematic review of desensitization strategies
    Spataro, Federico
    Carlucci, Palma
    Loverre, Teresa
    Macchia, Luigi
    Di Bona, Danilo
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2023, 34 (06)
  • [36] Hypersensitivity reaction during enzyme replacement therapy in lysosomal storage disorders: a systematic review of desensitization strategies Reply
    Spataro, Federico
    Carlucci, Palma
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2024, 35 (08)
  • [37] Therapy for Lysosomal Storage Disorders
    Beck, Michael
    IUBMB LIFE, 2010, 62 (01) : 33 - 40
  • [38] Enzyme therapy for the lysosomal storage disorders: principles, patents, practice and prospects
    Pastores, GM
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (08) : 1157 - 1172
  • [39] Enzyme replacement therapies in lysosomal storage diseases
    Germain, D. P.
    Boucly, C.
    Carlier, R. Y.
    Caudron, E.
    Charlier, P.
    Colas, F.
    Jabbour, F.
    Martinez, V.
    Mokhtari, S.
    Orlikowski, D.
    Pellegrini, N.
    Perronne, C.
    Prigent, H.
    Rubinsztajn, R.
    Benistan, K.
    REVUE DE MEDECINE INTERNE, 2010, 31 : S279 - S291
  • [40] Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
    David G Nathan
    Stuart H Orkin
    Genome Medicine, 1